The 18 references in paper M. Naumtseva S., B. Belov S., E. Aleksandrova N., G. Tarasova M., A. Novikov A., D. Karateev E., E. Luchikhina L., M. Cherkasova V., Yu. Murav'ev V., М. Наумцева С., Б. Белов С., Е. Александрова Н., Г. Тарасова М., А. Новиков А., Д. Каратеев Е., Е. Лучихина Л., М. Черкасова В., Ю. Муравьев В. (2016) “Оценка клинической эффективности, иммуногенности и безопасности 23-валентной пневмококковой вакцины у больных ревматоидным артритом // Assessment of clinical and immunological efficacy and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis” / spz:neicon:pulmonology:y:2015:i:6:p:720-724

1
Curtis J.R., Yang S., Patkar N.M. et al. Risk of hospitalized bacterial infections associated with biologic treatment among U.S. veterans with rheumatoid arthritis. Arthritis Care Res.2014; 66 (7): 990–997. DOI: 10.1002/acr.22281.
(check this in PDF content)
2
Widdifield J., Bernatsky S., Paterson J.M. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013; 65 (3): 353–361. DOI: 10.1002/acr.21812.
(check this in PDF content)
3
Koivuniemi R., Leirisalo-Repo M., Suomalainen R. et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand. J. Rheumatol. 2006; 35: 273–276.
(check this in PDF content)
4
Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis.2011; 70 (3): 414–422. DOI: 10.1136/ard.2010.137216.
(check this in PDF content)
5
Singh J.A., Furst D.E., Bharat A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res.2012; 64 (5): 625–639. DOI: 10.1002/ acr.21641.
(check this in PDF content)
6
Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis.2014; 58 (3): e44–100. DOI: 10.1093/cid/cit684.
(check this in PDF content)
7
Lanternier F., Henegar C., Mouthon L. et al. Low influenzavaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann. Rheum. Dis. 2008; 67 (7): 1047. DOI: 10.1136/ard.2007.081703. http://journal.pulmonology.ru723 Наумцева М.С. и др. Оценка клинической эффективности и безопасности 23-валентной пневмококковой вакцины
(check this in PDF content)
8
Pradeep J., Watts R., Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann. Rheum. Dis.2007; 66 (6): 837–838.
(check this in PDF content)
9
Dougados M., Soubrier M., Antunez A. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73 (1): 62–68. DOI:
(check this in PDF content)
10
1136/annrheumdis-2013-204223. 10. Aletaha D., Neogi T., Silman A.J. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Arthritis Rheum.2010; 62 (9): 2569–2581. DOI: 10.1002/art.27584.
(check this in PDF content)
11
Mori S., Ueki Y., Akeda Y. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann. Rheum. Dis. 2013; 72 (8): 1362–1366. DOI: 10.1136/annrheumdis-2012-202658.
(check this in PDF content)
12
Bingham C.O. 3rd, Rizzo W., Kivitz A. et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann. Rheum. Dis.2015; 74 (5): 818–822. DOI: 10.1136/annrheumdis-2013-204427.
(check this in PDF content)
13
Bengtsson C., Kapetanovich M.C., Kallberg H. et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann. Rheum. Dis. 2010; 69 (10): 1831–1833. DOI: 10.1136/ard.2010.129908.
(check this in PDF content)
14
Hmamouchi I., Winthrop K., Launay O. et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015; 33 (12): 1446–1452. DOI: 10.1016/j.vaccine. 2015.01.065.
(check this in PDF content)
15
Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. М.: МДВ; 2009: 252. / Kostinov M.P., Tarasova A.A. Vaccine prevention of pneumococcal infection and influenza in patients with autoimmune disease. Moscow: MDV; 2009: 252 (in Russian).
(check this in PDF content)
16
Kapetanovich M.С., Saxne T., Sjoholm A. et al. Influence of methotrexat, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide in patients with rheumatoid arthritis. Rheumatology. 2006; 45: 106–111. DOI: 10.1093/rheumatology/kei193.
(check this in PDF content)
17
Mori S., Ueki Y., Akeda Y. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann. Rheum. Dis.2013; 72 (8): 1362–1366. DOI: 10.1136/annrheumdis-2012-202658.
(check this in PDF content)
18
Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices: Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Morb. M
(check this in PDF content)